| Company Name: | Scolr Pharma, Incorporated | | Ticker Symbol: | DDD | | | WWW Address: | www.scolr.com | | CEO: | Stephen J. Turner | | No. of Employees: | 17 | | Common Issue Type: | CS | | Business Description: | A pharmaceutical company, which develops and formulates over-the-counter products, prescription drugs and dietary supplement products using its controlled delivery technology platform.
|
| | | Industry Information: | DRUGS - Diagnostic Support [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.5 |  -0.02 | 0.25 | 2.0 | 0.3165 | 0.56 | 0.51 | 23160 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 21.4 | 41.1 | 1.22 | -0.15 | 0.00 | 0.0 | 0.0 | 0.95 - 0.25 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.52 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 21.4 | mil |
| Latest Shares Outstanding | 41.1 | mil |
| Earnings pS (EPS) | -0.15 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 56,353 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 38.2 | mil |
| Float as % of Shares Outstanding | 93.0 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 568.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 483.40 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.1 | % |
| Return on Assets (ROA) | -196.1 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -254.2 | % |
| Current Ratio | 3.8 | |
| Leverage Ratio (Assets/Equity) | 1.3 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.04 | $ |
| Cash pS | 0.05 | $ |
| Book-Value pS | 0.08 | $ |
| Tangible Book-Value pS | 0.06 | $ |
| Cash Flow pS | -0.18 | $ |
| Free Cash Flow pS | -0.17 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 6.80 | |
| Price/Tangible Book Ratio | 8.29 | |
| Price/Cash Flow | -2.8 | |
| Price/Free Cash Flow | -3.0 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -14.8 | 84 | 1,081 | 749 |
| 4 Weeks | 0.85 | 0.25 | 0.46 | 13.0 | 106 | 660 | 11,212 |
| 13 Weeks | 0.85 | 0.25 | 0.34 | 52.9 | 142 | 478 | 29,172 |
| 26 Weeks | 0.85 | 0.25 | 0.33 | 57.6 | 131 | 421 | 52,685 |
| 52 Weeks | 0.95 | 0.25 | 0.80 | -34.8 | 53 | 442 | 110,010 |
| YTD | 0.85 | 0.25 | - | -20.0 | 65 | 413 | 93,777 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.63 | 0.63 | 0.52 | 0.41 | 0.41 | 1.22 | 0.75 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 10.95 | 9.7 | -26.01 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -4.18 | NA | -11.07 |
| R&D | 20.70 | NA | -13.61 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -15.0 | 10.7 | -51.4 |
| Earnings % | 0.0 | -100.0 | 0.0 |
| EPS % | 0.0 | -100.0 | 0.0 |
| EPS $ | -0.04 | -0.06 | 0.13 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 67.42 |
| Current Ratio | 6.9 |
| Quick Ratio (Acid Test) | 6.6 |
| Liquidity Ratio (Cash) | 6.39 |
| Receivables Turnover | 4.7 |
| Average Collection Period | 77 |
| Working Capital/Equity | 79.7 |
| Working Capital pS | 0.14 |
| Cash-Flow pS | -0.14 |
| Free Cash-Flow pS | -0.12 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 7.23 |
| Financial Leverage Ratio (Assets/Equity) | 1.2 |
| Debt Ratio | 15.4 |
| Total Debt/Equity (Gearing Ratio) | 0.02 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 4.5 |
| LT Debt/Total Liabilities | 1.7 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.18 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 2.32 |
| Tobin's Q Ratio | 2.47 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -1.65 |
| Enterprise Value (EV)/Free Cash Flow | -3.23 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 8.29 |
| Price/Book Ratio - LTM | 6.80 |
| Price/Cash Flow Ratio | -2.8 |
| Price/Free Cash Flow Ratio - LTM | -3.0 |
| Price/Sales Ratio | 25.39 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.02 |
| Tangible Book Value pS - LTM | 0.06 |
| Book Value pS - LTM | 0.08 |
| Capital Invested pS | 0.18 |
| Cash pS - LTM | 0.05 |
| Cash Flow pS - LTM | -0.18 |
| Free Cash Flow pS - LTM | -0.17 |
| Earnings pS (EPS) | -0.15 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -516.49 |
| Free Cash Flow Margin 5YEAR AVG | -748.30 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.13 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.13 |
| Return on Capital Invested (ROCI) | -83.6 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -69.6 |
| Assets Productivity | 0.10 |
| Return on Assets (ROA) | -71.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | -62.1 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 67 |
| Revenue per Employee | 56,353 |
| Net Income per Employee | -361,176 |
| Average Collection Period | 67 |
| Receivables Turnover | 4.7 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 24.95 |
| Assets/Revenue | 10.00 |
| Net Working Capital Turnover | 0.16 |
| Fixed Assets Turnover | 0.53 |
| Total Assets Turnover | 0.1 |
| Revenue per $ Cash | 0.15 |
| Revenue per $ Plant | 1.21 |
| Revenue per $ Common Equity | 0.13 |
| Revenue per $ Capital Invested | 0.13 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 524.9 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 382.4 |
| Research & Devlopment (R&D) as % of Revenue | 654.3 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 654.3 |
|
|  
|
| |
 |  |